LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Serum Levels of Lipoprotein Lipase Are Increased in Patients with Inflammatory Bowel Disease

    Orvelindo Rodríguez-Hernández / Marta Carrillo-Palau / Alejandro Hernández-Camba / Inmaculada Alonso-Abreu / Laura Ramos / Laura de Armas-Rillo / Candelaria Martín-González / Raquel López-Mejías / Miguel Á. González-Gay / Iván Ferraz-Amaro

    International Journal of Molecular Sciences, Vol 24, Iss 5194, p

    2023  Volume 5194

    Abstract: Disruption of the lipid profile is commonly found in patients with inflammatory bowel disease (IBD). Lipoprotein lipase (LPL) is a key molecule involved in triglyceride metabolism that plays a significant role in the progression of atherosclerosis. In ... ...

    Abstract Disruption of the lipid profile is commonly found in patients with inflammatory bowel disease (IBD). Lipoprotein lipase (LPL) is a key molecule involved in triglyceride metabolism that plays a significant role in the progression of atherosclerosis. In this study, our aim was to study whether serum LPL levels are different in IBD patients and controls and whether IBD features are related to LPL. This was a cross-sectional study that encompassed 405 individuals; 197 IBD patients with a median disease duration of 12 years and 208 age- and sex-matched controls. LPL levels and a complete lipid profile were assessed in all individuals. A multivariable analysis was performed to determine whether LPL serum levels were altered in IBD and to study their relationship with IBD characteristics. After the fully multivariable analysis, including cardiovascular risk factors and the changes in lipid profile that the disease causes itself, patients with IBD showed significantly higher levels of circulating LPL (beta coefficient 196 (95% confidence interval from 113 to 259) ng/mL, p < 0.001). LPL serum levels did not differ between Crohn’s disease and ulcerative colitis. However, serum C-reactive protein levels, disease duration, and the presence of an ileocolonic Crohn’s disease phenotype were found to be significantly and independently positively related to LPL. In contrast, LPL was not associated with subclinical carotid atherosclerosis. In conclusion, serum LPL levels were independently upregulated in patients with IBD. Inflammatory markers, disease duration and disease phenotype were responsible for this upregulation.
    Keywords inflammatory bowel disease ; lipoprotein lipase ; lipid profile ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Subject code 610
    Language English
    Publishing date 2023-03-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Hematological Composite Scores in Patients with Inflammatory Bowel Disease

    Marta Carrillo-Palau / Belén Vera-Santana / Andrea Morant-Domínguez / Alejandro Hernández-Camba / Laura Ramos / Inmaculada Alonso-Abreu / Noemi Hernández Álvarez-Buylla / Laura Arranz / Milagros Vela / Manuel Hernández-Guerra / Cristina Gómez-Moreno / Miguel Á. González-Gay / Iván Ferraz-Amaro

    Journal of Clinical Medicine, Vol 12, Iss 23, p

    2023  Volume 7248

    Abstract: The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and the systemic immune-inflammatory index (SIRI, neutrophils × monocytes/lymphocytes) have been identified as potential inflammatory ... ...

    Abstract The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and the systemic immune-inflammatory index (SIRI, neutrophils × monocytes/lymphocytes) have been identified as potential inflammatory biomarkers. In this work we aimed to analyze whether the hematological composite scores differ between inflammatory bowel disease (IBD) patients and healthy controls, and if they are related to disease activity. A total of 197 IBD patients—130 Crohn’s (CD) disease and 67 ulcerative colitis (UC)—and 208 age- and sex-matched healthy controls were enrolled. C-reactive protein and fecal calprotectin were assessed. Multivariable linear regression analysis was executed. After adjustment, NLR and PLR, but not SIRI and MLR, were significantly higher in IBD patients compared to controls. C-reactive protein and SIRI and NLR were correlated in IBD patients. However, fecal calprotectin was not related to any of these blood scores. Furthermore, disease activity parameters were not associated with any of the blood composite scores in both CD and UC patients. In conclusion, NLR and PLR, but not SIRI and MLR, are independently higher in IBD patients compared to controls. However, the four hematological scores are not related to disease activity in either CD or UC patients. Based on these results, blood-based inflammatory scores may not serve as subrogated biomarkers of disease activity in IBD.
    Keywords inflammatory bowel disease ; systemic immune-inflammatory index ; hematological inflammatory scores ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2023-11-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk

    Alejandro Hernández-Camba / Marta Carrillo-Palau / Laura Ramos / Noemi Hernández Alvarez-Buylla / Inmaculada Alonso-Abreu / Anjara Hernández-Pérez / Milagros Vela / Laura Arranz / Manuel Hernández-Guerra / Miguel Ángel González-Gay / Iván Ferraz-Amaro

    Journal of Clinical Medicine, Vol 10, Iss 1671, p

    2021  Volume 1671

    Abstract: The addition of carotid ultrasound into cardiovascular (CV) risk scores has been found to be effective in identifying patients with chronic inflammatory diseases at high-CV risk. We aimed to determine if its use would facilitate the reclassification of ... ...

    Abstract The addition of carotid ultrasound into cardiovascular (CV) risk scores has been found to be effective in identifying patients with chronic inflammatory diseases at high-CV risk. We aimed to determine if its use would facilitate the reclassification of patients with inflammatory bowel disease (IBD) into the very high-CV-risk category and whether this may be related to disease features. In this cross-sectional study encompassing 186 IBD patients and 175 controls, Systematic Coronary Risk Evaluation (SCORE), disease activity measurements, and the presence of carotid plaques by ultrasonography were assessed. Reclassification was compared between patients and controls. A multivariable regression analysis was performed to evaluate if the risk of reclassification could be explained by disease-related features and to assess the influence of traditional CV risk factors on this reclassification. After evaluation of carotid ultrasound, a significantly higher frequency of reclassification was found in patients with IBD compared to controls (35% vs. 24%, p = 0.030). When this analysis was performed only on subjects included in the SCORE low-CV-risk category, 21% IBD patients compared to 11% controls ( p = 0.034) were reclassified into the very high-CV-risk category. Disease-related data, including disease activity, were not associated with reclassification after fully multivariable regression analysis. Traditional CV risk factors showed a similar influence over reclassification in patients and controls. However, LDL-cholesterol disclosed a higher effect in controls compared to patients (beta coef. 1.03 (95%CI 1.02–1.04) vs. 1.01 (95%CI 1.00–1.02), interaction p = 0.035) after adjustment for confounders. In conclusion, carotid plaque assessment is useful to identify high-CV risk IBD patients.
    Keywords inflammatory bowel disease ; SCORE ; carotid plaques ; cardiovascular risk ; Medicine ; R
    Subject code 610 ; 616
    Language English
    Publishing date 2021-04-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease

    Marta Carrillo-Palau / Alejandro Hernández-Camba / Laura Ramos / Milagros Vela / Laura Arranz / Noemi Hernández Alvarez-Buylla / Inmaculada Alonso-Abreu / Anjara Hernández-Pérez / Manuel Hernández-Guerra / Camilo Palazuelos / Javier Llorca / Miguel Á. González-Gay / Iván Ferraz-Amaro

    Journal of Clinical Medicine, Vol 10, Iss 4102, p

    2021  Volume 4102

    Abstract: Inflammatory bowel disease (IBD) has been described as an independent risk factor for the development of cardiovascular (CV) disease. Since the QRESEARCH risk estimator version 3 (QRISK3) calculator was recently proposed to assess CV in the general ... ...

    Abstract Inflammatory bowel disease (IBD) has been described as an independent risk factor for the development of cardiovascular (CV) disease. Since the QRESEARCH risk estimator version 3 (QRISK3) calculator was recently proposed to assess CV in the general population, our objective was to compare the predictive ability of QRISK3 with that of a well-established European CV risk calculator, the Systematic Coronary Risk Assessment (SCORE), to identify the presence of subclinical carotid atherosclerosis in patients with IBD. In all, 186 patients with IBD and 178 controls were recruited. The presence of subclinical atherosclerosis was evaluated by carotid ultrasound to identify carotid plaque and the thickness of the carotid intima-media (cIMT). QRISK3 and SCORE were calculated. The relationship of QRISK3 and SCORE with each other and with the presence of subclinical carotid atherosclerosis (both carotid plaque and cIMT) was studied in patients and controls. SCORE (0.2 (interquartile range 0.1–0.9) vs. 0.4 (0.1–1.4), p = 0.55) and QRISK3 1.7 ((0.6–4.6) vs. 3.0 (1.0–7.8), p = 0.16) absolute values did not differ between patients and controls. QRISK3 and SCORE correlated equally with cIMT within both populations. However, SCORE correlation with cIMT was found to be significantly lower in patients with IBD when compared to controls (Spearman’s Rho 0.715 vs. 0.587, p = 0.034). Discrimination analysis of both calculators with carotid plaque was similar within both populations. Nevertheless, in patients with IBD, QRISK3 showed a trend toward a higher discrimination (QRISK3 area under the curve 0.812 (95%CI 0.748–0.875) vs. SCORE 0.790 (95%CI 0.723–0.856), p = 0.051). In conclusion, QRISK3 discrimination for subclinical atherosclerosis is optimal and equivalent to that of SCORE in IBD patients. However, our findings highlight the role of QRISK3 as an appropriate tool for the assessment of CV risk in patients with IBD.
    Keywords inflammatory bowel disease ; cardiovascular disease ; cardiovascular risk ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2021-09-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    María Chaparro / Iria Baston-Rey / Estela Fernández Salgado / Javier González García / Laura Ramos / María Teresa Diz-Lois Palomares / Federico Argüelles-Arias / Eva Iglesias Flores / Mercedes Cabello / Saioa Rubio Iturria / Andrea Núñez Ortiz / Mara Charro / Daniel Ginard / Carmen Dueñas Sadornil / Olga Merino Ochoa / David Busquets / Eduardo Iyo / Ana Gutiérrez Casbas / Patricia Ramírez de la Piscina /
    Marta Maia Boscá-Watts / Maite Arroyo / María José García / Esther Hinojosa / Jordi Gordillo / Pilar Martínez Montiel / Benito Velayos Jiménez / Cristina Quílez Ivorra / Juan María Vázquez Morón / José María Huguet / Yago González-Lama / Ana Isabel Muñagorri Santos / Víctor Manuel Amo / María Dolores Martín Arranz / Fernando Bermejo / Jesús Martínez Cadilla / Cristina Rubín de Célix / Paola Fradejas Salazar / Antonio López San Román / Nuria Jiménez / Santiago García-López / Anna Figuerola / Itxaso Jiménez / Francisco José Martínez Cerezo / Carlos Taxonera / Pilar Varela / Ruth de Francisco / David Monfort / Gema Molina Arriero / Alejandro Hernández-Camba / Francisco Javier García Alonso / Manuel Van Domselaar / Ramón Pajares-Villarroya / Alejandro Núñez / Francisco Rodríguez Moranta / Ignacio Marín-Jiménez / Virginia Robles Alonso / María del Mar Martín Rodríguez / Patricia Camo-Monterde / Iván García Tercero / Mercedes Navarro-Llavat / Lara Arias García / Daniel Hervías Cruz / Sebastian Kloss / Alun Passey / Cynthia Novella / Eugenia Vispo / Manuel Barreiro-de Acosta / Javier P. Gisbert

    Journal of Clinical Medicine, Vol 11, Iss 15, p

    2022  Volume 4518

    Abstract: Ustekinumab has shown efficacy in Crohn’s Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future trials. ... ...

    Abstract Ustekinumab has shown efficacy in Crohn’s Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future trials. The objective of this analysis was to determine whether baseline patient characteristics are predictive of remission and the drug durability of ustekinumab, and whether its positioning with respect to prior use of biologics has a significant effect after correcting for disease severity and phenotype at baseline using interpretable machine learning. Patients’ data from SUSTAIN, a retrospective multicenter single-arm cohort study, were used. Disease phenotype, baseline laboratory data, and prior treatment characteristics were documented. Clinical remission was defined as the Harvey Bradshaw Index ≤ 4 and was tracked longitudinally. Drug durability was defined as the time until a patient discontinued treatment. A total of 439 participants from 60 centers were included and a total of 20 baseline covariates considered. Less exposure to previous biologics had a positive effect on remission, even after controlling for baseline disease severity using a non-linear, additive, multivariable model. Additionally, age, body mass index, and fecal calprotectin at baseline were found to be statistically significant as independent negative risk factors for both remission and drug survival, with further risk factors identified for remission.
    Keywords Crohn’s Disease ; ustekinumab ; predictive factors ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2022-08-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain

    María Chaparro / Ana Garre / Andrea Núñez Ortiz / María Teresa Diz-Lois Palomares / Cristina Rodríguez / Sabino Riestra / Milagros Vela / José Manuel Benítez / Estela Fernández Salgado / Eugenia Sánchez Rodríguez / Vicent Hernández / Rocío Ferreiro-Iglesias / Ángel Ponferrada Díaz / Jesús Barrio / José María Huguet / Beatriz Sicilia / María Dolores Martín-Arranz / Xavier Calvet / Daniel Ginard /
    Inmaculada Alonso-Abreu / Luis Fernández-Salazar / Pilar Varela Trastoy / Montserrat Rivero / Isabel Vera-Mendoza / Pablo Vega / Pablo Navarro / Mónica Sierra / José Luis Cabriada / Mariam Aguas / Raquel Vicente / Mercè Navarro-Llavat / Ana Echarri / Fernando Gomollón / Elena Guerra del Río / Concepción Piñero / María José Casanova / Katerina Spicakova / Jone Ortiz de Zarate / Emilio Torrella Cortés / Ana Gutiérrez / Horacio Alonso-Galán / Álvaro Hernández-Martínez / José Miguel Marrero / Rufo Lorente Poyatos / Margalida Calafat / Lidia Martí Romero / Pilar Robledo / Orencio Bosch / Nuria Jiménez / María Esteve Comas / José María Duque / Ana María Fuentes Coronel / Manuela Josefa Sampedro / Eva Sesé Abizanda / Belén Herreros Martínez / Liliana Pozzati / Hipólito Fernández Rosáenz / Belén Crespo Suarez / Pilar López Serrano / Alfredo J. Lucendo / Margarita Muñoz Vicente / Fernando Bermejo / José Joaquín Ramírez Palanca / Margarita Menacho / Amalia Carmona / Raquel Camargo / Sandra Torra Alsina / Nuria Maroto / Juan Nerín de la Puerta / Elena Castro / Ignacio Marín-Jiménez / Belén Botella / Amparo Sapiña / Noelia Cruz / José Luis F. Forcelledo / Abdel Bouhmidi / Carlos Castaño-Milla / Verónica Opio / Isabel Nicolás / Marcos Kutz / Alfredo Abraldes Bechiarelli / Jordi Gordillo / Yolanda Ber / Yolanda Torres Domínguez / María Teresa Novella Durán / Silvia Rodríguez Mondéjar / Francisco J. Martínez-Cerezo / Lilyan Kolle / Miriam Sabat / Cesar Ledezma / Eduardo Iyo / Óscar Roncero / Rebeca Irisarri / Laia Lluis / Isabel Blázquez Gómez / Eva María Zapata / María José Alcalá / Cristina Martínez Pascual / María Montealegre / Laura Mata / Ana Monrobel / Alejandro Hernández Camba / Luis Hernández / María Tejada / Alberto Mir / María Luisa Galve / Marta Soler / Daniel Hervías / José Antonio Gómez-Valero / Manuel Barreiro-de Acosta / Fernando Rodríguez-Artalejo / Esther García-Esquinas / Javier P. Gisbert / on behalf of the EpidemIBD study group of GETECCU

    Journal of Clinical Medicine, Vol 10, Iss 2885, p

    Large-Scale Epidemiological Study

    2021  Volume 2885

    Abstract: 1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: ... ...

    Abstract (1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31–56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.
    Keywords epidemiology ; incidence ; inflammatory bowel disease ; Crohn’s disease ; ulcerative colitis ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2021-06-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top